Last reviewed · How we verify
OLT1177 Capsules — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
OLT1177 Capsules (OLT1177 Capsules) — Olatec Therapeutics LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| OLT1177 Capsules TARGET | OLT1177 Capsules | Olatec Therapeutics LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- OLT1177 Capsules CI watch — RSS
- OLT1177 Capsules CI watch — Atom
- OLT1177 Capsules CI watch — JSON
- OLT1177 Capsules alone — RSS
Cite this brief
Drug Landscape (2026). OLT1177 Capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/olt1177-capsules. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing